FDA opens access to Neurogenesis stem cell therapy for progressive MS
The FDA cleared Neurogenesis Bio's expanded access program, letting progressive MS patients outside its trials get the experimental stem cell therapy NG01. The University of Miami is the first site, and the first patient was screened this week. A planned Phase 2b trial starts next year.
- Original source: multiplesclerosisnewstoday.com.
- The source published it on Nov 19, 2026 at 5:01 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA has cleared Neurogenesis Bio to hand out its experimental stem cell therapy NG01 to people with progressive multiple sclerosis through an expanded access program. The pathway lets patients who can't get into the company's clinical trials receive an investigational treatment. The University of Miami is the first site, with more U.S. locations expected to follow.
Neurogenesis is already moving. The first patient has been screened and was set to have bone marrow aspiration — the opening step in making the therapy — this week, the company said. Guy Bar-Klein, Neurogenesis' senior vice president of clinical and strategy, called the FDA's green light a pivotal step for progressive MS patients with few options, and said expanded access lets the company responsibly extend NG01 beyond its trials.
The program runs alongside NG01's clinical push, including a planned Phase 2b trial (NCT06961383) slated to begin in the first half of next year. A $500,000 gift from the Mendoza Family Fund, set up with the National MS Society, helps fund the effort. CEO Tal Gilat credited the Mendoza family and the University of Miami, saying that kind of collaboration between science, medicine and community is what opens access to an investigational therapy for the people who need it most.
NG01 is autologous — built from a patient's own cells. Mesenchymal stem cells are collected from bone marrow, expanded, then injected into the spinal canal, where they're expected to reach areas of local inflammation. The therapy is designed to calm brain inflammation, protect nerve cells and recruit oligodendrocytes, the cells that make myelin. Neurologist Flavia Nelson at the University of Miami, who leads the expanded access program with Denise Pereira, said NG01 acts at the affected areas of the brain and spinal cord — precisely the biology that drives disability in progressive disease. Nelson will also serve as lead principal investigator on the Phase 2b trial.
The approach has data behind it. NG01 was tested in four completed studies, including a Phase 2 trial (NCT02166021) of 48 people with progressive MS — 41 with secondary progressive MS and seven with primary progressive MS. Patients who got NG01 were less likely to see disability progression, and the into-the-spinal-canal route outperformed the intravenous one on several measures. A later biomarker analysis found drops in neurofilament light chain, a marker of nerve cell damage, in the intrathecal group. Earlier this year, the FDA granted NG01 Regenerative Medicine Advanced Therapy designation for SPMS, a status meant to speed development and review of promising regenerative therapies for serious diseases.
TopicsNeurogenesis Bio · NG01 · FDA · University of Miami · National MS Society · Mendoza Family Fund · Flavia Nelson · Guy Bar-Klein
Source: multiplesclerosisnewstoday.com
Written by AI from verified reporting.
More stories
- Health & science adelaide.edu.au Caught by @boxlink 0 viewsAdelaide quantum team ditches hundreds of loops, keeps sensor sensitivity
- Health & science medicalxpress.com Caught by @ajayy30 0 viewsGut Bacterium's Sugar Burns Visceral Fat, Duke-Led Study Finds
- Health & science x.com 0 viewsFiona the hippo swallowed a knit cap, so the Cincinnati Zoo borrowed a horse farm's vibration plate
- Health & science clinicaladvisor.com 0 viewsFDA Clears Roche's Once-Daily Giredestrant for Hard-to-Treat Breast Cancer

